Standard InChI: InChI=1S/C25H28N4S/c1-27-10-12-28(13-11-27)8-4-9-29-18-24(23-5-2-3-6-25(23)29)22-15-21(16-26-17-22)20-7-14-30-19-20/h2-3,5-7,14-19H,4,8-13H2,1H3
1.Fraley ME, Arrington KL, Hambaugh SR, Hoffman WF, Cunningham AM, Young MB, Hungate RW, Tebben AJ, Rutledge RZ, Kendall RL, Huckle WR, McFall RC, Coll KE, Thomas KA.. (2003) Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors., 13 (18):[PMID:12941314][10.1016/s0960-894x(03)00627-9]
2.Jacquemard U, Dias N, Lansiaux A, Bailly C, Logé C, Robert JM, Lozach O, Meijer L, Mérour JY, Routier S.. (2008) Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents., 16 (9):[PMID:18439832][10.1016/j.bmc.2008.03.034]
3.Mondal D, Amin SA, Moinul M, Das K, Jha T, Gayen S.. (2022) How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors., 53 [PMID:34864496][10.1016/j.bmc.2021.116534]